Legal entity
Last mentioned: Mar 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
corporate-law is the sole category represented across all 1 tracked stories. Investors is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.4 for that window. Each story carries 2 original sources on average, compared with 3.1 for the broader beat in this window. We currently track 1 Legal story that mention Soleno Therapeutics, Inc., all published on March 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 57 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Soleno Therapeutics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Lead Counsel Appointment
Expected timeframe for the court to designate the lead plaintiff and legal representation.
Lead Plaintiff Deadline
Final day for affected investors to petition the court to lead the class action.
Lawsuit Announcements
Schall Law Firm files class action notices for Soleno Therapeutics and Ultragenyx Pharmaceutical.
The Schall Law Firm has initiated securities fraud class actions against Soleno Therapeutics and Ultragenyx Pharmaceutical, alleging violations of federal securities laws. The firm is currently seeking lead plaintiffs to represent the class in these high-stakes biotech litigations following potential misrepresentations to the market.
Source: prnewswire.com · prnewswire.com
Soleno Therapeutics, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
